Trials Begin for New Novel Immunotherapy in Melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

A clinical research study at Rosewell Park Cancer Institute (RPCI) will be examining a new novel immunotherapy approach to treating advanced melanoma. In testing the safety of the new immunotherapy, researchers hope to determine whether it may be used for treating patients with stage III or stage IV melanoma, and even solid tumor cancers. Rosewell Park Cancer Institute reports:

John M. Kane III, MD, FACS, a surgical oncologist who is Chief of the Melanoma/Sarcoma Service at RPCI, will lead the phase I clinical trial, which will enroll between 12 and 20 patients over the course of approximately three years. Participating patients with advanced melanoma will receive a series of three vaccinations over six weeks.

Read the full story here: http://bit.ly/13s7Shy